⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for carcinoma, renal cell

Every month we try and update this database with for carcinoma, renal cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell CancerNCT00282048
Kidney Neoplasm...
Carcinoma, Rena...
AG-013736 (axit...
18 Years - Pfizer
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerNCT01021059
Melanoma
Carcinoma, Rena...
rh IL-15
18 Years - 85 YearsNational Institutes of Health Clinical Center (CC)
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid TumorsNCT04572451
Melanoma
Carcinoma, Rena...
Unresectable So...
nivolumab
BMS-986253
Stereotactic Bo...
18 Years - University of Pittsburgh
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.NCT01398306
Carcinoma
Carcinoma, Rena...
Neuroendocrine ...
Carcinoid Tumor
Pancreatic Isle...
Blood sampling ...
18 Years - University Medical Center Groningen
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®NCT00771147
Carcinoma, Rena...
Carcinoma, Rena...
Sorafenib (Nexa...
18 Years - Bayer
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaNCT04028245
Carcinoma, Rena...
Spartalizumab
Canakinumab
18 Years - 99 YearsColumbia University
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell CarcinomaNCT00523640
Carcinoma, Rena...
combination of ...
18 Years - University of Chicago
RGD-PET-CT in Cancer AngiogenesisNCT01492192
Carcinoma, Rena...
18F-RGD-PET-CT ...
18 Years - Oxford University Hospitals NHS Trust
Mobile Intervention - Physical Activity in Cancer TreatmentNCT03671304
Carcinoma, Rena...
Fitbit Versa
18 Years - 89 YearsUniversity of Texas Southwestern Medical Center
VEG111485: A QTc Study of PazopanibNCT00861029
Carcinoma, Rena...
Pazopanib
Placebo for paz...
Moxifloxacin
Placebo for mox...
18 Years - GlaxoSmithKline
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney CancerNCT00440973
Carcinoma, Rena...
Bevacizumab
Interleukin-2
18 Years - The Methodist Hospital Research Institute
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell CarcinomaNCT00089648
Carcinoma, Rena...
Sunitinib
18 Years - Pfizer
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)NCT00043368
Melanoma
Breast Neoplasm...
Carcinoma, Rena...
Lymphoma, T-Cel...
Carcinoma, Non-...
PF-3512676
18 Years - Pfizer
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell CarcinomaNCT02386111
Carcinoma, Rena...
Kidney Diseases
Kidney Neoplasm...
Urogenital Neop...
Urologic Diseas...
Urologic Neopla...
Neoplasms
Neoplasms by Hi...
Clear-cell Meta...
Combination of ...
18 Years - Celldex Therapeutics
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell CancerNCT01189370
Renal Cell Canc...
sorafenib
18 Years - University of Kansas Medical Center
VEG111485: A QTc Study of PazopanibNCT00861029
Carcinoma, Rena...
Pazopanib
Placebo for paz...
Moxifloxacin
Placebo for mox...
18 Years - GlaxoSmithKline
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaNCT04028245
Carcinoma, Rena...
Spartalizumab
Canakinumab
18 Years - 99 YearsColumbia University
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)NCT02962804
Carcinoma, Rena...
Nivolumab
Radiation
18 Years - University of Kansas Medical Center
Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor ThrombusNCT01328691
Carcinoma, Rena...
Thrombus
18 Years - Seoul National University Hospital
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell CarcinomaNCT00244764
Carcinoma, Rena...
GW786034
Placebo
21 Years - GlaxoSmithKline
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell CarcinomaNCT00044564
Carcinoma, Rena...
Bay 59-8862
18 Years - Bayer
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell CarcinomaNCT00523640
Carcinoma, Rena...
combination of ...
18 Years - University of Chicago
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentNCT04338269
Carcinoma, Rena...
Atezolizumab
Cabozantinib
18 Years - Hoffmann-La Roche
Nexavar Dosing in Renal Cancer Patients in "Real-life" SettingNCT01557127
Carcinoma, Rena...
Sorafenib (Nexa...
18 Years - Bayer
Regulatory Post Marketing Surveillance Study on Nexavar®NCT01012011
Carcinoma, Hepa...
Carcinoma, Rena...
Sorafenib (Nexa...
20 Years - 91 YearsBayer
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)NCT04941768
Carcinoma, Rena...
18 Years - Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney CancerNCT00440973
Carcinoma, Rena...
Bevacizumab
Interleukin-2
18 Years - The Methodist Hospital Research Institute
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC PatientsNCT02324803
Self Efficacy
Adverse Drug Ev...
Carcinoma, Rena...
pazopanib
18 Years - Southern China Urology Cancer Consortium
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell CarcinomaNCT01339975
Carcinoma
Carcinoma Renal...
Kidney Neoplasm...
Kidney Diseases
Chemokines
Biological samp...
Biological samp...
18 Years - University Hospital, Bordeaux
KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other BiomarkersNCT04295174
Carcinoma, Rena...
18 Years - Odense University Hospital
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal MassesNCT02248389
Carcinoma, Rena...
Sonatherm 600i ...
18 Years - 80 YearsIndiana University
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingNCT03109015
Carcinoma, Rena...
Sunitinib
Sunitinib
18 Years - Duke University
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)NCT02627963
Carcinoma, Rena...
Tivozanib hydro...
Sorafenib
18 Years - AVEO Pharmaceuticals, Inc.
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell CarcinomaNCT00095186
Carcinoma, Rena...
Recombinant Hum...
18 Years - Agennix
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell CarcinomaNCT01677390
Renal Cell Carc...
SGN-75
everolimus
18 Years - Seagen Inc.
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)NCT02454478
Carcinoma, Rena...
Lenvatinib
Everolimus
20 Years - Eisai Inc.
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based TherapyNCT01195649
Carcinoma, Rena...
Sorafenib (Nexa...
18 Years - Bayer
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall InvasionNCT05589207
Carcinoma, Rena...
Tumor Thrombus
Neoplasm Invasi...
Inferior Vena C...
Vascular wall i...
18 Years - Peking University Third Hospital
RGD-PET-CT in Cancer AngiogenesisNCT01492192
Carcinoma, Rena...
18F-RGD-PET-CT ...
18 Years - Oxford University Hospitals NHS Trust
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional ImagingNCT00842790
Carcinoma, Rena...
18 Years - 85 YearsAssistance Publique - Hôpitaux de Paris
Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell CarcinomaNCT02782715
Carcinoma, Rena...
Stereotactic Bo...
Microwave Ablat...
18 Years - University of Wisconsin, Madison
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced CancersNCT05544929
Carcinoma, Non-...
Cutaneous Melan...
Carcinoma, Rena...
Carcinoma, Ovar...
Nasopharyngeal ...
Carcinoma, Thym...
Anal Cancer
Mesothelioma
Esophagogastric...
High Microsatel...
Squamous Cell C...
Triple Negative...
KFA115
pembrolizumab
18 Years - Novartis
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell CarcinomaNCT01147822
Carcinoma, Rena...
Pazopanib
Sunitinib
18 Years - Novartis
Savolitinib vs. Sunitinib in MET-driven PRCC.NCT03091192
Carcinoma
Carcinoma, Rena...
Kidney Neoplasm...
Urologic Neopla...
Kidney Diseases
Neoplasms by Si...
Enzyme Inhibito...
Protein Kinase ...
Savolitinib
Sunitinib
18 Years - 130 YearsAstraZeneca
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaNCT00111020
Carcinoma, Rena...
Sorafenib (Nexa...
15 Years - Bayer
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)NCT02962804
Carcinoma, Rena...
Nivolumab
Radiation
18 Years - University of Kansas Medical Center
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCNCT00522249
Carcinoma, Rena...
Pegylated Alfa ...
sunitinib
erlotinib
18 Years - The Methodist Hospital Research Institute
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)NCT04195750
Carcinoma, Rena...
Belzutifan
Everolimus
18 Years - Merck Sharp & Dohme LLC
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.NCT00077974
Carcinoma, Rena...
SU011248
18 Years - Pfizer
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaNCT05287945
Carcinoma, Rena...
Orellanine
18 Years - Oncorena AB
Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell CarcinomaNCT02417194
Carcinoma, Rena...
Pathology
Treatment Outco...
Hemoglobin A1c ...
20 Years - 80 YearsSeoul National University Hospital
Detection of Renal Malignancy of Complicated Renal CystsNCT01087060
Kidney Neoplasm
Cysts
Carcinoma, Rena...
partial or radi...
20 Years - 80 YearsSeoul National University Hospital
Safety Study of RAD001 to Treat Patients With Metastatic Kidney CancerNCT00446368
Carcinoma, Rena...
RAD001
18 Years - The Methodist Hospital Research Institute
Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal CarcinomaNCT05790122
Carcinoma, Rena...
Kidney Neoplasm...
18 Years - 80 YearsThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell CarcinomaNCT02732652
Carcinoma, Rena...
18 Years - Chalmers University of Technology
Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor.NCT03943771
Kidney Neoplasm...
Carcinoma, Rena...
Anxiety, renal ...
18 Years - University Hospital, Bordeaux
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)NCT00716625
Carcinoma, Rena...
sunitinib malat...
0 Days - Pfizer
A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesNCT04544748
Carcinoma, Non-...
Carcinoma, Rena...
Melanoma
GNR-051
18 Years - AO GENERIUM
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaNCT00130897
Carcinoma, Rena...
Sutent
18 Years - Pfizer
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell CarcinomaNCT00992121
Carcinoma, Rena...
Bevacizumab
Pazopanib 2 wee...
Pazopanib 3 wee...
18 Years - GlaxoSmithKline
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional ImagingNCT00842790
Carcinoma, Rena...
18 Years - 85 YearsAssistance Publique - Hôpitaux de Paris
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.NCT01441388
Carcinoma, Rena...
Glioblastoma
Carcinoma, Hepa...
Crizotinib plus...
Crizotinib plus...
Crizotinib plus...
Crizotinib plus...
Crizotinib plus...
Crizotinib plus...
Crizotinib plus...
18 Years - Pfizer
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell CarcinomaNCT02729194
Carcinoma, Rena...
Pazopanib
Low Fat Diet
18 Years - University of Michigan Rogel Cancer Center
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerNCT03111901
Carcinoma, Rena...
Melanoma
Pembrolizumab
Interleukin-2
18 Years - University of Virginia
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell CarcinomaNCT00056173
Carcinoma, Rena...
Metastases, Neo...
GTI-2040
18 Years - Aptose Biosciences Inc.
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal CancerNCT00445523
Carcinoma, Rena...
TroVax® (Immuno...
Interferon-alph...
18 Years - The Methodist Hospital Research Institute
A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesNCT04544748
Carcinoma, Non-...
Carcinoma, Rena...
Melanoma
GNR-051
18 Years - AO GENERIUM
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory CancerNCT00079612
Carcinoma, Rena...
Sorafenib (Nexa...
Placebo
18 Years - Bayer
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell CarcinomaNCT00044564
Carcinoma, Rena...
Bay 59-8862
18 Years - Bayer
A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsNCT02952989
Carcinoma, Non-...
Carcinoma, Rena...
Breast Neoplasm...
Urinary Bladder...
Carcinoma, Squa...
Colorectal Neop...
Gastric Adenoca...
Gastroesophagea...
SGN-2FF
pembrolizumab
18 Years - Seagen Inc.
A Research Study for Patients With Metastatic Renal Cell CarcinomaNCT00106613
Carcinoma, Rena...
Neoplasm Metast...
FK228 (romideps...
18 Years - Celgene
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerNCT01021059
Melanoma
Carcinoma, Rena...
rh IL-15
18 Years - 85 YearsNational Institutes of Health Clinical Center (CC)
A Study of Oncobax®-AK in Patients With Advanced Solid TumorsNCT05865730
Carcinoma, Rena...
Carcinoma, Non-...
Live Bacterial ...
18 Years - EverImmune
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerNCT05297734
End of Life
Cancer
Receive technol...
Receive redesig...
21 Years - Stanford University
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.NCT01024920
Carcinoma, Rena...
BIBF 1120
sunitinib
18 Years - Boehringer Ingelheim
Study Evaluating Renal Cell Carcinoma Risk FactorsNCT00927043
Carcinoma, Rena...
Epidemiological...
18 Years - Pfizer
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaNCT00353301
Renal Cell Carc...
Erlotinib hydro...
Sirolimus
18 Years - University of Colorado, Denver
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)NCT02014636
Carcinoma, Rena...
Pazopanib
MK-3475
18 Years - Novartis
Sorafenib Dose Escalation in Renal Cell CarcinomaNCT00618982
Carcinoma, Rena...
Sorafenib (Nexa...
18 Years - Bayer
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney CancerNCT00448149
Carcinoma, Rena...
RAD001
Sorafenib
18 Years - The Methodist Hospital Research Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: